Daniel O'Day, Chairman & CEO, highlighted "another very strong set of results for Gilead, closing out a remarkable year for the company with clinical, commercial and operational achievements that set ...
Good afternoon, everyone, and welcome to Gilead's Fourth Quarter and Full Year 2025 Earnings Conference Call. My name is Rebecca, and I'll be today's host. In a moment, we'll begin our prepared ...